Suheyla AYTAC ARSLAN, Gonca ALTİNİSİK INAN, Gulhan GULER AVCİ

Reirradiation with Cyberknife® fractionated stereotactic radiotherapy in adult recurrent low-grade gliomas

AbstractAim: We aimed to present our clinical experience in patients with recurrent LGG who underwent the fractionated stereotactic radiotherapy (FSRT) with Cyberknife®.Material and Methods: Ten patients with recurrent low grade glioma who had previously irradiated were treated with FSRT as a salvage treatment. At the initial diagnosis, the histology of the tumor was grade II astrocytoma or oligodendroglioma. Four of 10 patients underwent surgery as the primary treatment for recurrence.Results: The median prescription dose was 24 Gy (range 21-25 Gy) with a median fractionation number of 4 (range, 3-5 fractions). No concurrent chemotherapy was administered except one with radiological tumor upgrading. The median interval between the first diagnosis and recurrence was 95 months (range, 45-191 months). From the time point of re-irradiation, median survival was 15 months (range, 1-30 months). CyberKnife® FSRT was well tolerated by all patients. No acute or late side effects were recorded. With a median follow-up of 17 months, 3 patients died. Seven patients were alive with local tumor control in 5 and tumor progression in2 patients.Conclusion: Fractionated stereotactic radiotherapy is a safe and effective salvage treatment for recurrent LGG. FSRT in adult recurrent LGGs showed encouraging short term results in this small number of cases. Prospective studies are necessitated as further evaluation.

PDF

___

1. Sherman JH, Weintraub D, Lopes MBS, et al. LowGrade Gliomas. In: Norden AD et al editors. Primary central nervous system tumors, Pathogenesis and Therapy. Humane Press, NewYork 2011;173-94.
2. Louis DN, Ohgaki H, Wiestler OD, et al. The 200 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109.
3. Berger MS, Deliganis AV, Dobbins J et al. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 1994;74:1784 91.
4. Gousias K, Schramm J, Simon M. Extent of resection and survival in supratentorial infiltrative low grade gliomas: Analysis of and adjustment for treatment bias. Acta Neurochir (Wien) 2014;156:327-37.
5. Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low grade gliomas. JAMA 2012;308:1881-8.
6. Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long term outcome of low grade hemispheric gliomas. J Clin Oncol 2008;26:1338-45.
7. Zadeh G, Khan OH, Vogelbaum M, et al. Much debated controversies of diffuse low grade gliomas. Neuro Oncol 2015;17:323-6.
8. Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low grade gliomas in adults. J Neurosurg 2008;109:817- 24.
9. Daniels TB, Brown PD, Felten SJ, et al. Validation of EORTC prognostic factors for adults with low grade glioma: A report using intergroup 86 72 51. Int J Radiat Oncol Biol Phys 2011;81:218-24.
10. Gorlia T, Wu W, Wang M, et al: New validated prognostic models and prognostic calculators in patients with low grade gliomas diagnosed by central pathology review: A pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials. Neuro Oncol 2013;15:1568-79.
11. Dillon A. Guidance on the use of temozolomide for the treatment of recurrent malignant glioma. (brain cancer).NICE Technology Appraisal Guidance -National Institute for Clinical Excellence, UK, 2001.
12. Hentschel SJ, Sawaya R. Optimizing outcomes with maximal surgical resection of malignant gliomas. Cancer Control 2003;10:109-14.
13. Osman MA. Temozolomide and Reirradiation in Recurrent Grade II Brain Glioma. World J Oncol 2014;5:118-25.
14. Fukuya Y, Ikuta S, Maruyama T, et al. Tumor recurrence patterns after surgical resection of intracranial lowgrade gliomas. J Neurooncol 2019;144:519-28.
15. Sadik ZHA, Hanssens PEJ, Verheul JB, et al. Gammaknife radiosurgery for recurrent gliomas. J Neurooncol 2018;140:615-22.
16. Uppstrom TJ, Singh R, Hadjigeorgiou GF, et al. Repeat surgery for recurrent low-grade gliomas should be standard of care. Clin Neurol Neurosurg. 2016;151:18- 23.
17. Hanzély Z, Polgár C, Fodor J, et al. Role of early radiotherapy in thetreatment of supratentorial WHO Grade II astrocytomas: long-term results of 97 patients, J. Neurooncol 2003;63:305-12.
18. Spitaels J, Devriendt D, Sadeghi N, et al. Management of supratentorial recurrent low-grade glioma : A multidisciplinary experience in 35 adult patients. Oncol Lett. 2017;14:2789-95.
19. Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 2009;8:810-8.
20. Lee J, Ahn SS, Chang JH, et al. Hypofractionated Re-irradiation after Maximal Surgical Resection for Recurrent Glioblastoma: Therapeutic Adequacy and Its Prognosticators of Survival. Yonsei Med J 2018;59:194-201.
21. Scoccianti S, Francolini G, Carta GA, et al. Re-irradiation as salvage treatment in recurrent glioblastoma: A comprehensive literature review to provide practical answers to frequently asked questions. Crit Rev Oncol Hematol 2018;126:80-91.